females to follow finalist
RISING STAR IN ENTREPRENEURSHIP
Vanessa Vankerckhoven
Chief Executive Officer & Founder
Idevax
About Vanessa Vankerckhoven
I consider myself a passionate entrepreneur in the Life Sciences and MedTech sector. I’m Founder and CEO of Idevax, a Belgian drug delivery device company. I hold a PhD in Medical Sciences from the University of Antwerp, Belgium. I’m also a Guest Professor at the Faculty of Medicine & Health Sciences at the University of Antwerp. I have has a profound interest in vaccinology, medical microbiology, infectious diseases, oncology and medical devices.
Idevax is my second venture as prior to founding Idevax, I founded Novosanis as a MedTech & spin-off from the University of Antwerp, Belgium in 2013. I successfully led the company through its acquisition by Orasure Technologies Inc in Jan 2019 and remained CEO until October 2022.
I started my career as Research & Innovation Manager at the Vaccine and Infectious Disease Institute (VAXINFECTIO) at the University of Antwerp, Belgium.
About Idevax
Idevax is an ISO13845 certified Belgian medical device company specialising in innovative drug delivery solutions for prophylactic and therapeutic vaccine applications. Our flagship product line, VAX-ID®, is a CE-marked device suited for reliable, standardized, and user-independent skin drug delivery with minimal training and high degree of ease of use. FDA and WHO PQ are expected early 2026.
VAX-ID® is designed to support a broad spectrum of applications, including preventive vaccines like Rabies, Mpox, Polio, HPV as well as immunotherapies and cancer vaccines. With its unique ability to consistently deliver into the dermis, it offers important advantages such as supporting solid immunogenicity, dose-sparing strategies, and equitable access to vaccines.
Visit our website (www.idevax.com) or follow our LinkedIn page to discover more about Idevax. Let’s shape the future of reliable drug delivery together!
Idevax is an ISO13845 certified Belgian medical device company specialising in innovative drug delivery solutions for prophylactic and therapeutic vaccine applications. Our flagship product line, VAX-ID®, is a CE-marked device suited for reliable, standardized, and user-independent skin drug delivery with minimal training and high degree of ease of use. FDA and WHO PQ are expected early 2026.
VAX-ID® is designed to support a broad spectrum of applications, including preventive vaccines like Rabies, Mpox, Polio, HPV as well as immunotherapies and cancer vaccines. With its unique ability to consistently deliver into the dermis, it offers important advantages such as supporting solid immunogenicity, dose-sparing strategies, and equitable access to vaccines.
Visit our website (www.idevax.com) or follow our LinkedIn page to discover more about Idevax. Let’s shape the future of reliable drug delivery together!
| Powered by: Hyphen Projects BV | Connect with us | Join TOPX | |||
| Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 | | |
© Copyright 2020 by Hyphen Projects